Journal
TRANSLATIONAL LUNG CANCER RESEARCH
Volume 4, Issue 1, Pages 36-54Publisher
AME PUBLISHING COMPANY
DOI: 10.3978/j.issn.2218-6751.2014.05.01
Keywords
Non-small cell lung carcinoma; targeted therapy; epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK)
Categories
Ask authors/readers for more resources
In recent years, there has been a major paradigm shift in the management of non-small cell lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver mutation if one is known or present. Translational research advances now allow such mutations to be inhibited by either receptor monoclonal antibodies (mAb) or small molecule tyrosine kinase inhibitors (TKI). Whilst empirical chemotherapy with a platinum-doublet remains the gold standard for advanced NSCLC without a known driver mutation, targeted therapy is pushing the boundary to significantly improve patient outcomes and quality of life. In this review, we will examine the major subtypes of oncogenic drivers behind NSCLC as well as the development of targeted agents available to treat them both now and in the foreseeable future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available